Pharmaceutical Research, ISSN 0724-8741, 3/2019, Volume 36, Issue 3, pp. 1 - 14
Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart containing two additional excipients: niacinamide, to increase early...
Biochemistry, general | Biomedicine | oligomerization | absorption | fast-acting insulin aspart | vasodilation | Pharmacy | niacinamide | Medical Law | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | absorption; fast-acting insulin aspart; niacinamide; oligomerization; vasodilation | SUBCUTANEOUS INJECTION | GLYCEMIC CONTROL | PROFILES | HYDROTROPIC SOLUBILIZATION | NICOTINAMIDE | BLOOD-FLOW | CHEMISTRY, MULTIDISCIPLINARY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ONSET | Hypoglycemic Agents - pharmacokinetics | Endothelial Cells - metabolism | Humans | Cells, Cultured | Insulin Aspart - pharmacokinetics | Scattering, Small Angle | Subcutaneous Absorption - drug effects | Diabetes Mellitus, Type 1 - drug therapy | Dose-Response Relationship, Drug | Insulin Aspart - administration & dosage | Animals | Regional Blood Flow - drug effects | Hypoglycemic Agents - administration & dosage | Models, Biological | X-Ray Diffraction | Diabetes Mellitus, Type 1 - blood | Injections, Subcutaneous | Subcutaneous Tissue - blood supply | Female | Niacinamide - pharmacology | Vasodilation - drug effects | Subcutaneous Tissue - metabolism | Sus scrofa | Subcutaneous Tissue - drug effects | Oligomers | Niacinamide | Arginine | Swine | Vasodilators | Permeability | Insulin | Endothelium | Pharmacology | Stability analysis | Small angle X ray scattering | Arteries | Monomers | Endothelial cells | Vasodilation | Blood flow | X-ray scattering | Absorption | Perfusion | Skin | X ray scattering | Transport | Research Paper
Biochemistry, general | Biomedicine | oligomerization | absorption | fast-acting insulin aspart | vasodilation | Pharmacy | niacinamide | Medical Law | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | absorption; fast-acting insulin aspart; niacinamide; oligomerization; vasodilation | SUBCUTANEOUS INJECTION | GLYCEMIC CONTROL | PROFILES | HYDROTROPIC SOLUBILIZATION | NICOTINAMIDE | BLOOD-FLOW | CHEMISTRY, MULTIDISCIPLINARY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | ONSET | Hypoglycemic Agents - pharmacokinetics | Endothelial Cells - metabolism | Humans | Cells, Cultured | Insulin Aspart - pharmacokinetics | Scattering, Small Angle | Subcutaneous Absorption - drug effects | Diabetes Mellitus, Type 1 - drug therapy | Dose-Response Relationship, Drug | Insulin Aspart - administration & dosage | Animals | Regional Blood Flow - drug effects | Hypoglycemic Agents - administration & dosage | Models, Biological | X-Ray Diffraction | Diabetes Mellitus, Type 1 - blood | Injections, Subcutaneous | Subcutaneous Tissue - blood supply | Female | Niacinamide - pharmacology | Vasodilation - drug effects | Subcutaneous Tissue - metabolism | Sus scrofa | Subcutaneous Tissue - drug effects | Oligomers | Niacinamide | Arginine | Swine | Vasodilators | Permeability | Insulin | Endothelium | Pharmacology | Stability analysis | Small angle X ray scattering | Arteries | Monomers | Endothelial cells | Vasodilation | Blood flow | X-ray scattering | Absorption | Perfusion | Skin | X ray scattering | Transport | Research Paper
Journal Article
Diabetes, ISSN 0012-1797, 11/2014, Volume 63, Issue 11, pp. 3946 - 3954
Endogenous insulin secretion exposes the liver to three times higher insulin concentrations than the rest of the body. Because subcutaneous insulin delivery...
Insulin - pharmacology | Animals | Lipolysis - drug effects | Dogs | Lipid Metabolism - drug effects | Glucose - metabolism | Blood Glucose | Female | Glucagon - metabolism | Male | Insulin - analogs & derivatives | Glucose metabolism | Care and treatment | Fat metabolism | Metabolic diseases | Dosage and administration | Research | Insulin | Pharmacology and Therapeutics
Insulin - pharmacology | Animals | Lipolysis - drug effects | Dogs | Lipid Metabolism - drug effects | Glucose - metabolism | Blood Glucose | Female | Glucagon - metabolism | Male | Insulin - analogs & derivatives | Glucose metabolism | Care and treatment | Fat metabolism | Metabolic diseases | Dosage and administration | Research | Insulin | Pharmacology and Therapeutics
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1/2007, Volume 104, Issue 3, pp. 937 - 942
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes....
Molecules | Receptors | Dose response relationship | Knockout mice | Agonists | Ligands | Diabetes | Pancreas | Insulin | Insulin secretion | Allosteric | G protein-coupled receptor | Screening | Ago-allosteric modulator | cAMP | allosteric | screening | GLYCEMIC CONTROL | HEALTHY-SUBJECTS | MULTIDISCIPLINARY SCIENCES | INSULIN-SECRETION | PROTEIN-COUPLED RECEPTORS | ALLOSTERIC MODULATION | ALPHA-CELL | BETA-CELL FUNCTION | TYPE-2 DIABETIC-PATIENTS | BINDING-SITES | ago-allosteric modulator | NONPEPTIDE | Humans | Sulfones - pharmacology | Quinoxalines - pharmacology | Sulfones - chemistry | Thiadiazoles - chemistry | Glucagon-Like Peptides - chemistry | Molecular Structure | Drug Evaluation, Preclinical | Insulin Secretion | Thiadiazoles - pharmacology | Receptors, Glucagon - agonists | Receptors, Glucagon - genetics | Cricetinae | Cells, Cultured | Pancreas - drug effects | Quinoxalines - chemistry | Receptors, Glucagon - metabolism | Pancreas - metabolism | Mice, Knockout | Pancreas - surgery | Glucagon-Like Peptides - metabolism | Insulin - metabolism | Animals | Glucagon-Like Peptide-1 Receptor | Perfusion | Mice | Cyclic adenylic acid | Research | G proteins | Glucagon | Agonists (Biochemistry) | Biological Sciences
Molecules | Receptors | Dose response relationship | Knockout mice | Agonists | Ligands | Diabetes | Pancreas | Insulin | Insulin secretion | Allosteric | G protein-coupled receptor | Screening | Ago-allosteric modulator | cAMP | allosteric | screening | GLYCEMIC CONTROL | HEALTHY-SUBJECTS | MULTIDISCIPLINARY SCIENCES | INSULIN-SECRETION | PROTEIN-COUPLED RECEPTORS | ALLOSTERIC MODULATION | ALPHA-CELL | BETA-CELL FUNCTION | TYPE-2 DIABETIC-PATIENTS | BINDING-SITES | ago-allosteric modulator | NONPEPTIDE | Humans | Sulfones - pharmacology | Quinoxalines - pharmacology | Sulfones - chemistry | Thiadiazoles - chemistry | Glucagon-Like Peptides - chemistry | Molecular Structure | Drug Evaluation, Preclinical | Insulin Secretion | Thiadiazoles - pharmacology | Receptors, Glucagon - agonists | Receptors, Glucagon - genetics | Cricetinae | Cells, Cultured | Pancreas - drug effects | Quinoxalines - chemistry | Receptors, Glucagon - metabolism | Pancreas - metabolism | Mice, Knockout | Pancreas - surgery | Glucagon-Like Peptides - metabolism | Insulin - metabolism | Animals | Glucagon-Like Peptide-1 Receptor | Perfusion | Mice | Cyclic adenylic acid | Research | G proteins | Glucagon | Agonists (Biochemistry) | Biological Sciences
Journal Article
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 08/2007, Volume 17, Issue 15, p. 4144
Y-shaped molecules bearing alkynylallylic moieties were found to be potent and selective PPARdelta activators. The alkynylallylic moiety was synthesized from...
PPAR delta - agonists | Models, Molecular | Molecular Structure
PPAR delta - agonists | Models, Molecular | Molecular Structure
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 08/2007, Volume 17, Issue 15, p. 4144
Selective PPAR[delta] agonists, 6, were obtained by SAR study of structural changes of the PPARpan agonist 5.
Journal Article
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 08/2007, Volume 17, Issue 16, p. 4625
Structure based ligand design was used in order to design a partial agonist for the PPARdelta receptor. The maximum activation in the transactivation assay was...
Phenylurea Compounds - chemistry | Butyrates - pharmacology | PPAR delta - agonists | Butyrates - chemistry | Drug Design | Models, Molecular | Thiazoles - chemistry | Molecular Structure | Phenylurea Compounds - pharmacology | Structure-Activity Relationship | Thiazoles - pharmacology
Phenylurea Compounds - chemistry | Butyrates - pharmacology | PPAR delta - agonists | Butyrates - chemistry | Drug Design | Models, Molecular | Thiazoles - chemistry | Molecular Structure | Phenylurea Compounds - pharmacology | Structure-Activity Relationship | Thiazoles - pharmacology
Journal Article
Diabetes, ISSN 0012-1797, 06/2005, Volume 54, p. A239
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 07/2003, Volume 88, Issue 7, pp. 3227 - 3235
FSH is a key component in assisted reproductive technologies. Because of rapid clearance of the hormone, patients have to be treated with daily injections. To...
BIOLOGICAL CHARACTERIZATION | MEDIAN CHARGE | FOLLITROPIN BETA-SUBUNIT | ENDOCRINOLOGY & METABOLISM | IMPORTANT DETERMINANT | CHARGE HETEROGENEITY | HUMAN CHORIONIC-GONADOTROPIN | AMINO-ACID SEQUENCE | HUMAN PITUITARY FSH | RECEPTOR-BINDING | LUTEINIZING-HORMONE | Estradiol - blood | Follicle Stimulating Hormone - chemistry | Protein Structure, Tertiary | Cricetinae | Gene Expression | Ovary - anatomy & histology | Humans | Organ Size | Rats | Glycosylation | Rats, Sprague-Dawley | Animals | Follicle Stimulating Hormone - pharmacokinetics | Infertility, Female - drug therapy | Drug Design | Female | Ovary - drug effects | In Vitro Techniques | Follicle Stimulating Hormone - genetics | CHO Cells
BIOLOGICAL CHARACTERIZATION | MEDIAN CHARGE | FOLLITROPIN BETA-SUBUNIT | ENDOCRINOLOGY & METABOLISM | IMPORTANT DETERMINANT | CHARGE HETEROGENEITY | HUMAN CHORIONIC-GONADOTROPIN | AMINO-ACID SEQUENCE | HUMAN PITUITARY FSH | RECEPTOR-BINDING | LUTEINIZING-HORMONE | Estradiol - blood | Follicle Stimulating Hormone - chemistry | Protein Structure, Tertiary | Cricetinae | Gene Expression | Ovary - anatomy & histology | Humans | Organ Size | Rats | Glycosylation | Rats, Sprague-Dawley | Animals | Follicle Stimulating Hormone - pharmacokinetics | Infertility, Female - drug therapy | Drug Design | Female | Ovary - drug effects | In Vitro Techniques | Follicle Stimulating Hormone - genetics | CHO Cells
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2009, Volume 52, Issue 9, pp. 2989 - 3000
The aim of the work presented here was to design and synthesize potent human glucagon receptor antagonists with improved pharmacokinetic (PK) properties for...
DIABETES-MELLITUS | PATHOGENESIS | POTENT | CHEMISTRY, MEDICINAL | ALKYLIDENE HYDRAZIDES | HYPERGLYCEMIA | SOLID-PHASE SYNTHESIS | MICE | OPTIMIZATION | DISCOVERY | GLUCOSE-PRODUCTION | Cell Line | Thiazoles - metabolism | Receptors, Glucagon - antagonists & inhibitors | Species Specificity | Administration, Oral | Humans | Half-Life | Receptors, Glucagon - metabolism | Thiazoles - pharmacokinetics | Animals | Drug Design | Thiazoles - chemistry | Thiazoles - pharmacology | Diabetes Mellitus, Type 2 - drug therapy
DIABETES-MELLITUS | PATHOGENESIS | POTENT | CHEMISTRY, MEDICINAL | ALKYLIDENE HYDRAZIDES | HYPERGLYCEMIA | SOLID-PHASE SYNTHESIS | MICE | OPTIMIZATION | DISCOVERY | GLUCOSE-PRODUCTION | Cell Line | Thiazoles - metabolism | Receptors, Glucagon - antagonists & inhibitors | Species Specificity | Administration, Oral | Humans | Half-Life | Receptors, Glucagon - metabolism | Thiazoles - pharmacokinetics | Animals | Drug Design | Thiazoles - chemistry | Thiazoles - pharmacology | Diabetes Mellitus, Type 2 - drug therapy
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 04/2007, Volume 50, Issue 7, pp. 1495 - 1503
The aim was to identify a novel selective PPARδ agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo....
ACTIVATED-RECEPTOR-DELTA | SKELETAL-MUSCLE | CELLS | BETA/DELTA | CHEMISTRY, MEDICINAL | ACID | PIOGLITAZONE | ACCURATE DOCKING | ALPHA | 3,4,5-TRISUBSTITUTED ISOXAZOLES | EXPRESSION
ACTIVATED-RECEPTOR-DELTA | SKELETAL-MUSCLE | CELLS | BETA/DELTA | CHEMISTRY, MEDICINAL | ACID | PIOGLITAZONE | ACCURATE DOCKING | ALPHA | 3,4,5-TRISUBSTITUTED ISOXAZOLES | EXPRESSION
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 2007, Volume 17, Issue 15, pp. 4144 - 4149
Selective PPARδ agonists, , were obtained by SAR study of structural changes of the PPARpan agonist . Y-shaped molecules bearing alkynylallylic moieties were...
Nuclear receptor | Substituted allyl alcohols | Peroxisome proliferator-activated receptor δ | PPAR agonists | Hydroalumination | CHEMISTRY, MEDICINAL | PEROXISOME PROLIFERATOR | CHEMISTRY, ORGANIC | hydroalumination | peroxisome proliferator-activated receptor delta | FATTY-ACIDS | IDENTIFICATION | HORMONE RECEPTOR SUPERFAMILY | PIOGLITAZONE | METABOLISM | ACCURATE DOCKING | CHLORIDES | nuclear receptor | 3,4,5-TRISUBSTITUTED ISOXAZOLES | DERIVATIVES | substituted allyl alcohols
Nuclear receptor | Substituted allyl alcohols | Peroxisome proliferator-activated receptor δ | PPAR agonists | Hydroalumination | CHEMISTRY, MEDICINAL | PEROXISOME PROLIFERATOR | CHEMISTRY, ORGANIC | hydroalumination | peroxisome proliferator-activated receptor delta | FATTY-ACIDS | IDENTIFICATION | HORMONE RECEPTOR SUPERFAMILY | PIOGLITAZONE | METABOLISM | ACCURATE DOCKING | CHLORIDES | nuclear receptor | 3,4,5-TRISUBSTITUTED ISOXAZOLES | DERIVATIVES | substituted allyl alcohols
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 08/2007, Volume 17, Issue 16, pp. 4625 - 4629
Structure based ligand design was used in order to design a partial agonist for the PPARδ receptor. The maximum activation in the transactivation assay was...
Design | Docking | Agonist | Partial | PPARd | ACTIVATION | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | GLIDE | agonist | docking | IN-VITRO | PIOGLITAZONE | METABOLISM | ACCURATE DOCKING | design | partial | PEROXISOME
Design | Docking | Agonist | Partial | PPARd | ACTIVATION | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | GLIDE | agonist | docking | IN-VITRO | PIOGLITAZONE | METABOLISM | ACCURATE DOCKING | design | partial | PEROXISOME
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 2007, Volume 17, Issue 11, pp. 3198 - 3202
Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARα agonists. Optimum PPARα...
PPARα | Docking | Agonist | docking | CHEMISTRY, MEDICINAL | ACCURATE DOCKING | CHEMISTRY, ORGANIC | PPAR alpha | GLIDE | agonist
PPARα | Docking | Agonist | docking | CHEMISTRY, MEDICINAL | ACCURATE DOCKING | CHEMISTRY, ORGANIC | PPAR alpha | GLIDE | agonist
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 04/2007, Volume 50, Issue 7, p. 1495
The aim was to identify a novel selective PPARdelta agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo....
Humans | Transcriptional Activation | Crystallography, X-Ray | Male | Structure-Activity Relationship | Muscle, Skeletal - cytology | Phenylacetates - pharmacokinetics | Fatty Acids, Nonesterified - metabolism | Cholesterol Ester Transfer Proteins - genetics | Phenylacetates - chemical synthesis | Dietary Fats - administration & dosage | Female | Binding Sites | Allyl Compounds - chemical synthesis | Cell Line | Allyl Compounds - pharmacokinetics | Oxidation-Reduction | Administration, Oral | Models, Molecular | Rats | Mice, Transgenic | Allyl Compounds - pharmacology | Apolipoprotein B-100 - genetics | Animals | PPAR delta - agonists | Lipid Metabolism - drug effects | Mice | Phenylacetates - pharmacology
Humans | Transcriptional Activation | Crystallography, X-Ray | Male | Structure-Activity Relationship | Muscle, Skeletal - cytology | Phenylacetates - pharmacokinetics | Fatty Acids, Nonesterified - metabolism | Cholesterol Ester Transfer Proteins - genetics | Phenylacetates - chemical synthesis | Dietary Fats - administration & dosage | Female | Binding Sites | Allyl Compounds - chemical synthesis | Cell Line | Allyl Compounds - pharmacokinetics | Oxidation-Reduction | Administration, Oral | Models, Molecular | Rats | Mice, Transgenic | Allyl Compounds - pharmacology | Apolipoprotein B-100 - genetics | Animals | PPAR delta - agonists | Lipid Metabolism - drug effects | Mice | Phenylacetates - pharmacology
Journal Article
Bioorganic & medicinal chemistry letters, ISSN 0960-894X, 06/2007, Volume 17, Issue 11, p. 3198
Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARalpha agonists. Optimum...
Computers | Phenylpropionates - pharmacology | Animals | Phenylpropionates - chemistry | Drug Design | Phenylpropionates - chemical synthesis | Ligands | PPAR alpha - agonists | Crystallography | PPAR alpha - chemistry
Computers | Phenylpropionates - pharmacology | Animals | Phenylpropionates - chemistry | Drug Design | Phenylpropionates - chemical synthesis | Ligands | PPAR alpha - agonists | Crystallography | PPAR alpha - chemistry
Journal Article
Proceedings of the National Academy of Sciences, USA, ISSN 0027-8424, 01/2007, Volume 104, Issue 3, pp. 937 - 942
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes....
Journal Article
Nucleic Acids Research, ISSN 0305-1048, 03/1988, Volume 16, Issue 5, pp. 2127 - 2148
Journal Article
JAMA Neurology, ISSN 2168-6149, 2019, Volume 76, Issue 6, pp. 641 - 649
IMPORTANCE The rationale for intravenous thrombolysis in patients with lacunar infarcts is debated, since it is hypothesized that the microvascular occlusion...
HEMORRHAGIC TRANSFORMATION | PROFILES | RISK-FACTORS | THERAPY | TISSUE-PLASMINOGEN ACTIVATOR | EFFICACY | ALTEPLASE | SUBTYPES | ACUTE ISCHEMIC-STROKE | IDENTIFICATION | CLINICAL NEUROLOGY | Occlusion | Stroke | Signs and symptoms | Nuclear magnetic resonance--NMR | Medical imaging | Intravenous administration | Effectiveness | Clinical trials | Pharmacology | Hemorrhage | Patients | Thrombolysis | Subgroups | Heterogeneity | Randomization | Reperfusion | Magnetic resonance imaging | Safety engineering | Resonance | Microvasculature | Safety
HEMORRHAGIC TRANSFORMATION | PROFILES | RISK-FACTORS | THERAPY | TISSUE-PLASMINOGEN ACTIVATOR | EFFICACY | ALTEPLASE | SUBTYPES | ACUTE ISCHEMIC-STROKE | IDENTIFICATION | CLINICAL NEUROLOGY | Occlusion | Stroke | Signs and symptoms | Nuclear magnetic resonance--NMR | Medical imaging | Intravenous administration | Effectiveness | Clinical trials | Pharmacology | Hemorrhage | Patients | Thrombolysis | Subgroups | Heterogeneity | Randomization | Reperfusion | Magnetic resonance imaging | Safety engineering | Resonance | Microvasculature | Safety
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2012, Volume 97, Issue 8, pp. E1524 - E1531
Context: Human granulosa cells (GC) acquire LH receptor (LHR) expression during the follicular phase of the menstrual cycle. Currently, the precise follicular...
LUTEINIZING-HORMONE RECEPTOR | INHIBIN-B | STIMULATING-HORMONE | MESSENGER-RNA | CHORIONIC-GONADOTROPIN | ENDOCRINOLOGY & METABOLISM | FOLLICULAR-FLUID | DOWN-REGULATION | ANDROGEN PRODUCTION | FSH | ANTI-MULLERIAN HORMONE | Estradiol - analysis | Progesterone - analysis | Receptors, FSH - genetics | Humans | Gene Expression Regulation | Ovulation | Follicular Fluid - chemistry | Granulosa Cells - metabolism | Aromatase - genetics | Receptors, LH - genetics | Cumulus Cells - metabolism | Adolescent | Adult | Female | Child | Advances in Genetics | JCEM Online
LUTEINIZING-HORMONE RECEPTOR | INHIBIN-B | STIMULATING-HORMONE | MESSENGER-RNA | CHORIONIC-GONADOTROPIN | ENDOCRINOLOGY & METABOLISM | FOLLICULAR-FLUID | DOWN-REGULATION | ANDROGEN PRODUCTION | FSH | ANTI-MULLERIAN HORMONE | Estradiol - analysis | Progesterone - analysis | Receptors, FSH - genetics | Humans | Gene Expression Regulation | Ovulation | Follicular Fluid - chemistry | Granulosa Cells - metabolism | Aromatase - genetics | Receptors, LH - genetics | Cumulus Cells - metabolism | Adolescent | Adult | Female | Child | Advances in Genetics | JCEM Online
Journal Article
Frontiers in Endocrinology, ISSN 1664-2392, 01/2018, Volume 8
Regulation of human ovarian steroidogenesis differs from other species and precise knowledge on how human small antral follicles (hSAF) develop and acquire...
Follicle-stimulating hormone | Inhibin-B | Granulosa cells | Luteinizing hormone | Human small antral follicles | Paracrine signaling | Follicular fluid | Human ovarian steroidogenesis | THECAL ANDROGEN PRODUCTION | follicle-stimulating hormone | paracrine signaling | inhibin-B | RECEPTOR GENE-EXPRESSION | granulosa cells | ANTI-MULLERIAN HORMONE | INHIBIN-B SECRETION | luteinizing hormone | INTERSTITIAL CELLS | follicular fluid | human ovarian steroidogenesis | ENDOCRINOLOGY & METABOLISM | human small antral follicles | CORRESPONDING GRANULOSA-CELLS | PLASMA PROTEIN-A | SINGLE-NUCLEOTIDE POLYMORPHISMS | NORMAL MENSTRUAL-CYCLE | GROWTH-FACTOR-I
Follicle-stimulating hormone | Inhibin-B | Granulosa cells | Luteinizing hormone | Human small antral follicles | Paracrine signaling | Follicular fluid | Human ovarian steroidogenesis | THECAL ANDROGEN PRODUCTION | follicle-stimulating hormone | paracrine signaling | inhibin-B | RECEPTOR GENE-EXPRESSION | granulosa cells | ANTI-MULLERIAN HORMONE | INHIBIN-B SECRETION | luteinizing hormone | INTERSTITIAL CELLS | follicular fluid | human ovarian steroidogenesis | ENDOCRINOLOGY & METABOLISM | human small antral follicles | CORRESPONDING GRANULOSA-CELLS | PLASMA PROTEIN-A | SINGLE-NUCLEOTIDE POLYMORPHISMS | NORMAL MENSTRUAL-CYCLE | GROWTH-FACTOR-I
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.